Literature DB >> 2301282

The prognostic implication of thymoma histologic subtyping. A study of 80 consecutive cases.

E Pescarmona1, E A Rendina, F Venuta, C Ricci, L P Ruco, C D Baroni.   

Abstract

In this study the authors have investigated the clinicopathologic correlations in 80 consecutive cases of thymoma in order to establish the clinical usefulness of histologic subtyping of these tumours. All cases were histologically examined and classified according to Salyer and Eggleston and to Marino and Müller-Hermelink classifications. Therefore, thymomas were subtyped as predominantly lymphocytic, mixed and predominantly epithelial and cortical, mixed and medullary, respectively. The frequency of the different histologic subtypes was determined, and histologic findings were related to patients' age, surgical stage, and survival. Through the application of Salyer and Eggleston classification, the three histologic subtypes did not correlate with patients' ages at time of diagnosis, surgical stage as determined by local infiltration, and prognosis as determined by survival curves. On the contrary, when Marino and Müller-Hermelink classification was applied, statistically significant relationships between histologic results and age, surgical stage, and prognosis were demonstrated. These results and their implications are discussed, with special reference to the important problem of histogenesis of thymomas and of their clinicopathologic staging.

Entities:  

Mesh:

Year:  1990        PMID: 2301282     DOI: 10.1093/ajcp/93.2.190

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Thymic epithelial tumors can develop along two different pathogenetic pathways.

Authors:  R Zhou; A Zettl; P Ströbel; K Wagner; H K Müller-Hermelink; S Zhang; A Marx; P Starostik
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 2.  Thymoma and thymic carcinoma.

Authors:  Federico Venuta; Erino A Rendina; Marco Anile; Tiziano de Giacomo; Domenico Vitolo; Giorgio F Coloni
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-01-13

3.  Thymoma: a review of the clinical and pathological findings in 65 cases.

Authors:  Brita Sperling; Jeff Marschall; Renee Kennedy; Punam Pahwa; Rajnl Chibbar
Journal:  Can J Surg       Date:  2003-02       Impact factor: 2.089

4.  Clinical and pathologic predictors of survival in patients with thymoma.

Authors:  K B Wilkins; E Sheikh; R Green; M Patel; S George; M Takano; M Diener-West; J Welsh; S Howard; F Askin; G B Bulkley
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

5.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

6.  Well-differentiated thymic carcinoma: a clinico-pathological study.

Authors:  E Pescarmona; S Rosati; E A Rendina; F Venuta; C D Baroni
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Neoplastic thymic epithelial cells of human thymoma support T cell development from CD4-CD8- cells to CD4+CD8+ cells in vitro.

Authors:  M Inoue; Y Fujii; M Okumura; Y Takeuchi; H Shiono; S Miyoshi; H Matsuda; R Shirakura
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

8.  Observer variation in the histopathological classification of thymoma: correlation with prognosis.

Authors:  A Dawson; N B Ibrahim; A R Gibbs
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

9.  P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: treatment response to chemotherapy with cyclosporin and quinine.

Authors:  J L Gala; H Noël; J Rodhain; D F Ma; A Ferrant
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411

10.  Prognostic factors of patients with thymoma.

Authors:  W S Lee; D S Heo; Y J Bang; K S Lee; J S Ahn; C W Jung; S K Han; S W Sung; J H Kim; Y S Shim; C I Park; N K Kim
Journal:  Korean J Intern Med       Date:  1996-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.